Stay updated on Lazertinib Combination in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lazertinib Combination in NSCLC Clinical Trial page.

Latest updates to the Lazertinib Combination in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now displays Revision: v3.4.2, replacing the previous v3.4.1; no other content or navigation changes are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoChange DetectedA version tag was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedShow glossary is now available and metadata labels were added or renamed (Last Update Submitted that Met QC Criteria, Last Update Posted) along with a revision tag (v3.4.0). Core study data and functionality remain unchanged, to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision label changed from v3.3.3 to v3.3.4. This is a minor metadata update and does not affect study details or user-facing content.SummaryDifference0.0%

- Check60 days agoChange DetectedMilestone dates on the study page have been updated: 2025-12-24, 2025-12-18, and 2028-03-27 were added, while 2025-12-04, 2025-12-05, and 2026-06-03 were removed.SummaryDifference0.1%

- Check67 days agoChange DetectedAdded a new Locations section listing state sites; removed the prior California through Washington location entries. The page revision was updated to v3.3.3.SummaryDifference0.7%

Stay in the know with updates to Lazertinib Combination in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib Combination in NSCLC Clinical Trial page.